ReviewBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2022
Meyerozyma guilliermondii species complex: review of current epidemiology, antifungal resistance, and mechanisms.
Review in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 27 citations in OpenAlex.
- Captive lizards (Squamata: Sauria) as reservoirs of medically important and antifungal-resistant yeasts.Medical mycology · 2026Article
- Agricultural fungicides shape soil and sediment reservoirs of multidrug-resistant fungi.Nature communications · 2026Article
- Snapshot reflection of the seasonal resilience and diversity of fungal phylotypes in the tropical Ikogosi spring.Environmental science and pollution research international · 2026Article
- Antifungal Susceptibility of ClinicalPathogens (Basel, Switzerland) · 2026Article
- From discovery to application: twenty years of Meyerozyma caribbica.FEMS yeast research · 2026Review
- An update on clinically relevant, rare, and emergingClinical microbiology reviews · 2025Review
- Hidden highways: fungi associated with glossiphoniid leeches.International journal for parasitology. Parasites and wildlife · 2025Article
- Changing Climate, ChangingJournal of fungi (Basel, Switzerland) · 2025Review
- Epidemiology and antifungal susceptibilities of rare yeast infections in a tertiary care center.BMC microbiology · 2025Article
- Virulence profile of pathogenic yeasts from snakes: Alternative ways for antifungal strategies.PloS one · 2025Article
- Prevalence, associated factors and etiologic agents of oral candidiasis among HIV-positive patients in a Vietnamese general hospital.Current medical mycology · 2024Article
- The role of fruits as reservoirs for resistant and virulent strains of opportunistic yeasts.World journal of microbiology & biotechnology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meyerozyma guilliermondii has been accepted as a complex composed of Meyerozyma guilliermondii, Meyerozyma carpophila, and Meyerozyma caribbica. M. guilliermondii is a saprophyte detected on human mucosa and skin. It can lead to serious infections in patients with risk factors like chemotherapy, immunodeficiency, gastrointestinal or cardiovascular surgery, and oncology disorders. Most deaths related to M. guilliermondii infections occur in individuals with malignancy. In recent decades, incidence of M. guilliermondii infections is increased. Sensitivity of this microorganism to conventional antifungals (e.g., amphotericin B, fluconazole, micafungin and anidulafungin) was reduced. Prophylactic and empirical uses of these drugs are linked to elevated minimal inhibitory concentrations (MICs) of M. guilliermondii. Drug resistance has concerned many researchers across the world. They are attempting to discover appropriate solution to combat this challenge. This study reviews the most important mechanisms of resistance to antifungals developed by in M. guilliermondii species complex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.